

## PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY

To:  
 MARK D. MOORE  
 WILLIAMS, MORGAN & AMERSON, P.C.  
 10333 RICHMOND, SUITE 1100  
 HOUSTON, TX 77042

PCT

DOCKETING DEPT.  
 SEP 10 2003  
 WILLIAMS, MORGAN & AMERSON

NOTIFICATION OF TRANSMITTAL OF  
THE INTERNATIONAL SEARCH REPORT  
OR THE DECLARATION

(PCT Rule 44.1)

		Date of Mailing (day/month/year)	05 SEP 2003
Applicant's or agent's file reference 4300.014510		FOR FURTHER ACTION See paragraphs 1 and 4 below	
International application No. PCT/US03/12324		International filing date (day/month/year)	
Applicant UNIVERSITY OF FLORIDA		21 April 2003 (21.04.2003)	

1.  The applicant is hereby notified that the international search report has been established and is transmitted herewith.

**Filing of amendments and statement under Article 19:**

The applicant is entitled, if he so wishes, to amend the claims of the international application (see Rule 46):

**When?** The time limit for filing such amendments is normally two months from the date of transmittal of the international search report.

**Where?** Directly to the International Bureau of WIPO, 34, chemin des Colombettes  
1211 Geneva 20, Switzerland, Facsimile No.: (41-22) 740.14.35

For more detailed instructions, see the notes on the accompanying sheet.

2.  The applicant is hereby notified that no international search report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.

3.  With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:

the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.  
 no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

## 4. Reminders

Shortly after 18 months from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90 bis.1 and 90 bis.3, respectively, before the completion of the technical preparations for international publication.

Within 19 months from the priority date, but only in respect of some designated Offices, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later); otherwise the applicant must, within 20 months from the priority date, perform the prescribed acts for entry into the national phase before those designated Offices.

In respect of other designated Offices, the time limit of 30 months (or later) will apply even if no demand is filed within 19 months.

See the Annex to Form PCT/IB/301 and, for details about the applicable time limits, Office by Office, see the *PCT Applicant's Guide*, Volume II, National Chapters and the WIPO Internet site.


Name and mailing address of the ISA/US  
 Mail Stop PCT, Attn: ISA/US  
 Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 Facsimile No. (703) 305-3230

Form PCT/ISA/220 (April 2002)

Authorized officer

Scott D. Priebe

Telephone No. (703) 308-0196



(See notes on accompanying sheet)

## INTERNATIONAL COOPERATION TREATY

## PCT

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 4300.014510	<b>FOR FURTHER ACTION</b>	see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.
International application No. PCT/US03/12324	International filing date (day/month/year) 21 April 2003 (21.04.2003)	(Earliest) Priority Date (day/month/year) 19 April 2002 (19.04.2002)
Applicant UNIVERSITY OF FLORIDA		

This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This international search report consists of a total of 7 sheets.



It is also accompanied by a copy of each prior art document cited in this report.

1. **Basis of the Report**
  - a. With regard to the language, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.
 
  
 the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).
  - b. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of the sequence listing:
  contained in the international application in written form.
  filed together with the international application in computer readable form.
  furnished subsequently to this Authority in written form.
  furnished subsequently to this Authority in computer readable form.
  the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
  the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.
2.  **Certain claims were found unsearchable (See Box I).**
3.  **Unity of invention is lacking (See Box II).**
4. With regard to the title,
  the text is approved as submitted by the applicant.
  the text has been established by this Authority to read as follows:
5. With regard to the abstract,
  the text is approved as submitted by the applicant.
  the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.
6. The figure of the drawings to be published with the abstract is Figure No. \_\_\_\_\_
  as suggested by the applicant.
  because the applicant failed to suggest a figure.
  because this figure better characterizes the invention.
  None of the figures

**INTERNATIONAL SEARCH REPORT**

International application No.

PCT/US03/12324

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(7) : A61K 48/00; C12N 15/15, 15/19, 15/85, 15/864  
US CL : 424/93.2, 93.21; 435/320.1

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/93.2, 93.21; 435/320.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
Please See Continuation Sheet

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99/055564 A1 (UNIVERSITY OF FLORIDA) 04 November 1999 (04.11.99), page 2, lines 22-31; pages 7-11; pages 21-25; Figures 1, 15-25.	1-7, 9, 11-13, 15, 17-26, 28-42
---		-----
Y		8, 10, 14, 16, 27, 1-7, 15-26, 28-42
A, X	KAPTURCZAK et al. Adeno-associated virus (AAV) as a vehicle for therapeutic gene delivery: Improvements in vector design and viral production enhance potential to prolong graft survival in pancreatic islet cell transplantation for the reversal of type 1 diabetes. Current Molecular Medicine. May 2001, Vol. 1, No. 2, pages 245-258, see entire document, especially page 251.	-----
---		8-14
Y		
X	SONG et al. Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors. Proceedings of the National Academy of Sciences USA. November 1998, Vol. 95, pages 14384-14388, see entire document.	1, 3, 7, 9, 12, 13, 15-21, 24-26, 28-30, 32-37
---		
X	FLOTTE et al. Efficient ex vivo transduction of pancreatic islet cells with recombinant adeno-associated virus vectors. Diabetes. March 2001, Vol. 50, No. 3, pages 515-520.	1-3, 5-7, 9, 11-13, 15-26, 28, 29, 32
---		-----
Y		33-42



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier application or patent published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

20 August 2003 (20.08.2003)

Date of mailing of the international search report

05 SEP 2003

Name and mailing address of the ISA/US  
Mail Stop PCT, Attn: ISA/US  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
Facsimile No. (703)305-3230

Authorized officer

Scott D. Priebe

Telephone No. (703) 308-0196

## INTERNATIONAL SEARCH REPORT

## C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SONG et al. Stable therapeutic serum levels of human alpha-1-antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors. <i>Gene Therapy</i> . September 2001, Vol. 8, pages 1299-1306, see entire document.	1, 3, 7, 9, 12, 13, 15-21, 24-26, 28-30, 32-37
X	GOUDY et al. Adeno-associated virus vector-mediated IL-10 gene delivery prevents type 1 diabetes in NOD mice. <i>Proceedings of the National Academy of Sciences USA</i> . 20 November 2001, Vol. 98, No. 24, pages 13913-13918, see entire document.	1-3, 5-7, 9, 11-13, 15-26, 28, 29-42
Y	US 6,136,597 A (HOPE et al.) 24 October 2000 (24.10.2000), col. 2, lines 50-67; col. 10, lines 1-9; col. 14, lines 5-22 and 53-63; col. 18, lines 6-32; col. 32, claim 11.	13
P, X	APPARAILLY et al. Tetracycline-inducible interleukin-10 gene transfer mediated by an adeno-associated virus: application to experimental arthritis. <i>Human Gene Therapy</i> . 01 July 2002, Vol. 13, No. 10, pages 1179-1188, see entire document.	1-3, 5-7, 9, 13, 15-26, 28-37
P, X	YANG et al. Suppression of autoimmune diabetes by viral IL-10 gene transfer. <i>Journal of Immunology</i> . 2002, Vol. 168, pages 6479-6485, see entire document.	1-3, 5-7, 9, 11-13, 15-26, 28, 29-42
P, Y	MAH et al. Improved method of recombinant AAV2 delivery for systemic targeted gene delivery. <i>Molecular Therapy</i> . July 2002, Vol. 6, No. 1, pages 106-112, see entire document.	27

INTERNATIONAL SEARCH REPORT

PCT/US03/1

**Continuation of B. FIELDS SEARCHED Item 3:**

USPT, PGPB, DERWENT, MEDLINE, EMBASE, BIOSIS, CAPLUS, SCISEARCH  
search terms: AAV, adeno-associated, diabetes, pancreas, islet, interleukin, IL, actin promoter, woodchuck, cytokine, AAT, antitrypsin, Atkinson M, Flotte T

# BEST AVAILABLE COPY

## NOTES TO FORM PCT/ISA/220

These Notes are intended to give the basic instructions concerning the filing of amendments under Article 19. The Notes are based on the requirements of the Patent Cooperation Treaty and of the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these Notes, "Article", "Rule" and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions, respectively.

### INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international publication. Furthermore, it should be emphasized that provisional protection is available in some States only.

What parts of the international application may be amended?

The claims only.

The description and the drawings may only be amended during international preliminary examination under Chapter II.

When? Within 2 months from the date of transmission of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been filed, see below.

How? Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

What documents must/may accompany the amendments?

Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether:

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

# BEST AVAILABLE COPY

## NOTES TO FORM PCT/ISA/220 (continued)

The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

1. [Where originally there were 48 claims and after amendment of some claims there are 51]:  
"Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
2. [Where originally there were 15 claims and after amendment of all claims there are 11]:  
"Claims 1 to 15 replaced by amended claims 1 to 11."
3. [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]:  
"Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or  
"Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
4. [Where various kinds of amendments are made]:  
"Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

### "Statement under Article 19(1)" (Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 12(1)).

The statement will be published with the international application and the amended claims.

The statement should be brief, it should not exceed 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It should not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report, may be made only in connection with an amendment of that claim.

### In what language?

The amendments must be made in the language in which the international application is published. The letter and any statement accompanying the amendments must be in the same language as the international application if that language is English or French; otherwise, it must be in English or French, at the choice of the applicant.

### Consequence if a demand for international preliminary examination has already been filed?

If, at the time of filing any amendments under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the same time of filing the amendments with the International Bureau, also file a copy of such amendments with the International Preliminary Examining Authority (see Rule 62.2(a), first sentence).

### Consequence with regard to translation of the international application for entry into the national phase?

The applicant's attention is drawn to the fact that, where upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see Volume II of the PCT Applicant's Guide.